Erika P. Hamilton, MD

Thought leaders in breast oncology share closing remarks about the future management of HER2+ BC with brain metastases with key insights on unmet needs and evolving treatment approaches.

Expert Perspectives on Updates in HER2+ BC Presented at the 2022 ASCO Annual Meeting

Erika P. Hamilton, MD;Rita Nanda, MD;Tiffany A. Traina, MD;Ryan Jones, MD

August 3rd 2022

Expert panelists discuss insights on HER2+ BC from the 2022 ASCO Annual Meeting including safety updates from DESTINY-BREAST03, data on the potential prognostic value of TILs, and trials on local therapy for oligometastatic disease.

Challenges Associated With Treating Leptomeningeal Disease in HER2+ mBC

Erika P. Hamilton, MD;Rita Nanda, MD;Tiffany A. Traina, MD;Ryan Jones, MD

August 3rd 2022

A panel of experts examines the challenges associated with treating leptomeningeal metastases in patients with HER2+ mBC including difficulties with using intrathecal chemotherapy and radiation therapy.

Treatment Strategies in Patients with HER2+ BC and Active vs Progressive Brain Metastases

Erika P. Hamilton, MD;Rita Nanda, MD;Tiffany A. Traina, MD;Ryan Jones, MD

July 27th 2022

Rita Nanda, MD, reflects on the use of systemic treatment with tucatinib in patients with visceral and CNS disease, and Ryan Jones, MD, discusses the evolving role of concurrent systemic therapy with radiosurgery.

Clinical Case 3: A Patient with HER2+ BC and Brain Metastases Treated with Tucatinib

Erika P. Hamilton, MD;Rita Nanda, MD;Tiffany A. Traina, MD;Ryan Jones, MD

July 27th 2022

Highlighting the clinical scenario of a 29-year-old woman with breast cancer, Tiffany Traina, MD, leads a discussion on challenges associated with accurate biomarker testing, tumor heterogeneity, and repeat biopsies.

The Role of the Radiation Oncologist in the Treatment of HER2+ BC and Brain Metastases

Erika P. Hamilton, MD;Rita Nanda, MD;Tiffany A. Traina, MD;Ryan Jones, MD

July 20th 2022

Key opinion leaders in the management of breast cancer discuss the role of the radiation oncologist in treating patients with brain metastases.

Selecting and Sequencing Tucatinib and T-DXd in HER2+ BC and Brain Metastases

Erika P. Hamilton, MD;Rita Nanda, MD;Tiffany A. Traina, MD;Ryan Jones, MD

July 20th 2022

Centralizing the conversation on trastuzumab deruxtecan, panelists comment on treatment toxicity and factors to consider when sequencing therapies in later lines of treatment.

Clinical Case 2: A Patient with HER2+ BC and Brain Metastases Treated with T-DXd

Erika P. Hamilton, MD;Rita Nanda, MD;Tiffany A. Traina, MD;Ryan Jones, MD

July 13th 2022

To discuss treatment options beyond the frontline setting, Erika Hamilton, MD, presents the clinical scenario of a 43-year-old woman with HER2+ mBC who progressed on paclitaxel/trastuzumab/pertuzumab.

Is There a Role for SRS and WBRT for Brain Metastases in HER2+ BC?

Erika P. Hamilton, MD;Rita Nanda, MD;Tiffany A. Traina, MD;Ryan Jones, MD

July 13th 2022

Ryan Jones, MD, reflects on factors to consider when selecting stereotactic radiosurgery vs whole-brain radiotherapy including performance status, extracranial control, number of lesions, and CNS progression.

Optimizing Outcomes in Patients with HER2+ BC with Current and Novel Therapies

Erika P. Hamilton, MD;Rita Nanda, MD;Tiffany A. Traina, MD;Ryan Jones, MD

July 6th 2022

A panel of experts discusses factors to consider when selecting treatment for patients with HER2+ mBC including brain metastases, quality of life, and treatment resistance.

Selecting the Appropriate Treatment for Patients with HER2+ mBC in Frontline and Beyond

Erika P. Hamilton, MD;Rita Nanda, MD;Tiffany A. Traina, MD;Ryan Jones, MD

July 6th 2022

Focusing discussion on the first clinical scenario, panelists examine currently available first- and second-line treatment approaches for HER2+ mBC.

Clinical Case 1: A 41-year-old Patient with HER2+ Metastatic Breast Cancer

Erika P. Hamilton, MD;Rita Nanda, MD;Tiffany A. Traina, MD;Ryan Jones, MD

June 29th 2022

Rita Nanda, MD, leads a discussion of the first clinical scenario, a 41-year-old woman with HER2+ metastatic breast cancer who progressed on docetaxel/trastuzumab/pertuzumab.

Overview of HER2+ Metastatic Breast Cancer (mBC)

Erika P. Hamilton, MD;Rita Nanda, MD;Tiffany A. Traina, MD;Ryan Jones, MD

June 29th 2022

To begin the program, an expert panel of leaders in the management of HER2+ metastatic breast cancer provides an overview of the disease landscape.

How Can We Optimize Treatment of HER2-Positive Metastatic Breast Cancer?

Erika P. Hamilton, MD;Kimberly L. Blackwell, MD

March 15th 2013

Third, how much do we really know about de novo and acquired resistance to trastuzumab and lapatinib? There are several possible clinical relevant mechanisms of trastuzumab resistance, including crosstalk with other receptors, amplification of the PI3K/AKT pathway, alteration of the trastuzumab binding domain, and loss of HER2 expression.